Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Tocris Bioscience™ JTE 607 Dihydrochloride
Cytokine release inhibitor; anti-inflammatory
Supplier: Tocris Bioscience™ 5185/50
This item is not returnable.
View return policy
Description
JTE 607 dihydrochloride is a pro-drug that is cleaved by carboxylesterase 1 (CES1) to its active metabolite, which then binds to cleavage and polyadenylation specificity factor 3 (CPSF3; Kd = 370 nM at human CPSF3). Treatment of A-673 cells with JTE 607 results in inhibition of mRNA cleavage and accumulation of nuclear R-loops. JTE 607 induces apoptosis in leukemia cells in vitro and prolongs survival in a mouse leukemia model. JTE 607 inhibits cytokine release and inhibits production of IL-1β, IL-8, IL-6, IL-10 and TNFα (IC50 values are 5.9, 7.3, 8.8, 9.1 and 11.0 nM, respectively) from LPS-stimulated PBMCs. In a rat model of lung injury, JTE 607 reduces proinflammatory cytokine-release and attenuates lung permeability.Specifications
JTE 607 dihydrochloride | |
N-[3,5-Dichloro-2-hydroxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]benzoyl]-L-phenylalanine ethyl ester dihydrochloride | |
Soluble to 100mM in water and to 100mM in DMSO | |
597.36 | |
Bioactive Small Molecule |
188791-09-5 | |
50 mg | |
C25H31Cl2N3O5·2HCl | |
Solid | |
>98% |
Safety and Handling
Recommended Storage : Desiccate at Room Temperature
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Research Use Only. Not For Human or Veterinary Use
Spot an opportunity for improvement?
Provide Content Correction